Highlight Day 2-Central Nervous System Tumors
advertisement
Highlights of the Day:<br />Central Nervous System Tumors Presented By Michael Prados at 2014 ASCO Annual Meeting Slide 2 Presented By Michael Prados at 2014 ASCO Annual Meeting R9802 SCHEMA Presented By Michael Prados at 2014 ASCO Annual Meeting Data Maturity Presented By Michael Prados at 2014 ASCO Annual Meeting Progression-Free Survival<br />ASCO 2014 Presented By Michael Prados at 2014 ASCO Annual Meeting Overall Survival<br />ASCO 2014 Presented By Michael Prados at 2014 ASCO Annual Meeting ASCO 2014: Overall Survival Presented By Michael Prados at 2014 ASCO Annual Meeting Cox Proportional Hazards Model for Overall Survival <br />(n=251) Presented By Michael Prados at 2014 ASCO Annual Meeting Conclusions (Prognostic Variables) Presented By Michael Prados at 2014 ASCO Annual Meeting Conclusions (Survival)<br /> Presented By Michael Prados at 2014 ASCO Annual Meeting Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779)/RT followed by CCI-779 versus chemo-irradiation with temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II study. Presented By Michael Prados at 2014 ASCO Annual Meeting EORTC 26082/22081: Study Design Presented By Michael Prados at 2014 ASCO Annual Meeting EORTC 26082/22081: Overall survival Presented By Michael Prados at 2014 ASCO Annual Meeting Conclusions Presented By Michael Prados at 2014 ASCO Annual Meeting Correlation of Molecular Subtypes <br />with Survival in AVAglio Presented By Michael Prados at 2014 ASCO Annual Meeting Introduction Presented By Michael Prados at 2014 ASCO Annual Meeting AVAglio Trial Design and Primary Endpoints Presented By Michael Prados at 2014 ASCO Annual Meeting ITT and Biomarker-Evaluable Populations Presented By Michael Prados at 2014 ASCO Annual Meeting Background: Glioblastoma Gene Expression Subtypes Presented By Michael Prados at 2014 ASCO Annual Meeting Results: BEV Treatment Impacted PFS in Proneural and Mesenchymal Subtypes Presented By Michael Prados at 2014 ASCO Annual Meeting Results: BEV Effect on OS was Evident Only in the Proneural Subtype Presented By Michael Prados at 2014 ASCO Annual Meeting Results: Effect of BEV on OS was Significant in Univariate and Multivariate Analyses Presented By Michael Prados at 2014 ASCO Annual Meeting Conclusions Presented By Michael Prados at 2014 ASCO Annual Meeting
